Myelodysplastic syndrome
Not recruitingStudy of luspatercept in patients with low-risk myelodysplastic syndrome (MDS) who do not require blood transfusions and have not received erythropoiesis treatment
Study of luspatercept in patients with low-risk myelodysplastic syndrome (MDS) who do not require blood transfusions and have not received erythropoiesis treatment
- Disease:Myelodysplastic syndrome
- Substances:Luspatercept
Germany- Participants:18–64 years · 65+ years
- Substances:Luspatercept
- Sponsor:University of Leipzig








